Navigation Links
BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
Date:2/1/2011

and joint abnormalities, which limit mobility and endurance. Malformation of the thorax impairs respiratory function, and odontoid hypoplasia and ligamentous laxity cause cervical spinal instability and potential cord compression. Other symptoms may include hearing loss, corneal clouding, and heart valvular disease. Initial symptoms often become evident in the first five years of life.  Depending on severity of the disease, age of diagnosis will vary.

The rate of incidence of MPS IVA is as yet unconfirmed and varies among different populations but estimates vary between 1 in 200,000 live births and 1 in 250,000 live births. There are several studies that have documented the incidence as high as 1 in 76,000 live births in Northern Ireland. The estimated prevalence is between 1,000 and 1,500 patients in the U.S., EU and Japan and between 1,500 to 2,000 patients in the rest of the world for a total of 2,500 to 3,500 patients. Over 1,000 MPS IVA patients worldwide have been identified through The International Morquio Organization (IMO) survey and the BioMarin MorCAP registry program.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Synd
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... , Aug. 3, 2015  Lexicon Pharmaceuticals, Inc. ... pivotal TELESTAR Phase 3 clinical trial met its ... etiprate in treating cancer patients with carcinoid syndrome ... standard of care. Telotristat etiprate was discovered using ... and is the company,s first discovery to complete ...
(Date:7/31/2015)... , July 31, 2015  Seeger Weiss LLP is ... (FDA) issued a warning letter to C.R. Bard, the manufacturer ... taking adequate strides to correct violations the agency found at ... these violations after the FDA cited them during Inspectional Observations ... in Bard,s Tempe, AZ , location and ...
(Date:7/31/2015)... July 31, 2015 RnRMarketResearch.com ... market research report that provides an overview of ... data sourced from in-house databases, secondary and primary ... needles market products pipeline spread across 124 pages, ... 73 tables and 5 figures is now available ...
Breaking Medicine Technology:Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
(Date:8/1/2015)... (PRWEB) , ... August 02, 2015 , ... Back packs ... in a school, however, back packs can wreck havoc on a kid's spine. With ... their supplies to and from school. Make sure you are aware of how to ...
(Date:8/1/2015)... ... ... Have you ever wondered what “Karma” really means? Does it even exist? Can I change ... tradition, which gave birth to Hinduism, is one of the most ancient spiritual and mystical ... According to the wisdom of this heritage, Karma is a very real and powerful force ...
(Date:8/1/2015)... ... 2015 , ... Calvary Hospital today announced that it is embarking on a ... is to bring this Torah – dating from 1880 – back to kosher status, ... , Scroll No. 515, from the town of Taus-Domazlice, is on permanent loan ...
(Date:8/1/2015)... ... August 01, 2015 , ... Brig and Lita Hart, icons of the network ... their Healthy Home mission with the HOPE Movement of EvolvHealth. In what has been ... companies have agreed to join their missions of purpose together to change the course ...
(Date:8/1/2015)... ... , ... On Tuesday, July 28th, Symantec released a security industry whitepaper ... the attack on Anthem Inc. which resulted in one of the largest data breaches ... spear phishing campaigns. , For Joe Caruso, founder and CEO/CTO of ...
Breaking Medicine News(10 mins):Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Nithyananda Yoga Foundation to Conduct Global Webinar on Karma at No Charge on August 1st 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4
... Prenatal Solution Key Factor in Decision for ... Jan. 8 Allscripts announced today that ... multi-specialty group practices in the Southeast United ... Health Record (EHR) to automate and connect ...
... Hospital have demonstrated a more effective treatment for ... antibiotics clindamycin and azithromycin, which kill bacteria by ... a standard first-line treatment with the "beta-lactam" antibiotic ... burst. , The finding is important ...
... 8 Allscripts-Misys Healthcare,Solutions, Inc., formerly Allscripts Healthcare ... financial results for the three and six,months ended ... (Logo: http://www.newscom.com/cgi-bin/prnh/20061005/ALLSCRIPTSLOGO-b ) , ... six months ended November 30, 2008,include results from ...
... 8 /PRNewswire-Asia/ -- Chindex International, Inc.,(Nasdaq: CHDX ... of Western healthcare products and services in the People,s ... the 2009 UBS Greater,China Conference, to be held in ... The 2009 UBS Greater China Conference will ...
... should be used when assessing traditional risk factors, experts say ... -- or "biomarkers" -- of inflammation may provide useful information ... research says. , "If you are very high or very ... said study lead author Dr. Vijay Nambi, a cardiologist at ...
... business continues to drive overall performanceDALLAS, Jan. 8 ... leader in hosted services for email encryption and e-prescribing, ... officer, Rick Spurr."We ended the year on a high ... the highest orders for the year in the fourth ...
Cached Medicine News:Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 3Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 4Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 4Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 5Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 6Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 7Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 8Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 9Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 10Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 11Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 12Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 13Health News:Chindex International Inc. Announces Participation in the 2009 UBS Greater China Conference 2Health News:Inflammation Markers May Help Predict Stroke Risk 2Health News:Inflammation Markers May Help Predict Stroke Risk 3Health News:Zix Corporation CEO Provides Corporate Update for Q4 and Year-End 2008 2Health News:Zix Corporation CEO Provides Corporate Update for Q4 and Year-End 2008 3Health News:Zix Corporation CEO Provides Corporate Update for Q4 and Year-End 2008 4
... Sterile E*Kits® can be a valuable ... care; when the items necessary for a ... facility protocols and continuum of care are ... are packaged in sequence of use, allowing ...
... to dry trays to specialty vaginal & ... Health offers the widest offering in patient ... that are proven to be safe and ... surgical site infections. Cardinal Health Scrub Care ...
The applicator is designed for a smooth delivery of the solution for surgical procedures....
... The Anti-HTLV Mixed Titer Performance Panel ... from weak to strong positive for antibodies ... is intended for use by manufacturers and ... assays. Comprehensive data from all major test ...
Medicine Products: